Association of Serum CXCL13 with Intrarenal Ectopic Lymphoid Tissue Formation in Lupus Nephritis
Table 1
Clinical data of the B-cell group and the non-B-cell group in LN patients.
LN-B-cell )
LN-non-B-cell )
// value
value
Male
8 (11.6)
3 (15.0)
0.786
0.294
Age (years)
−1.542
0.144
Duration (months)
2.185
0.045
Urine protein# (mg/24 h)
3 689.5 (1 568.7~8 686.5)
1785.6 (965.8~3 516.5)
−0.679
0.497
Serum Cr (umol/L)
0.277
0.785
C3 (mg/L)
0.966
0.350
C4 (mg/L)
0.956
0.354
Anti-dsDNA# (Iu/mL)
282.5 (115.6~418.6)
312.5 (135.6~462.5)
−0.341
0.733
WHO classification
0.263
0.877
LN (III)
16 (23.2)
5 (25.0)
LN (IV)
42 (60.9)
11 (55.0)
LN (V)
11 (15.9)
4 (20.0)
CI score
0.559
0.584
AI score
0.569
0.578
SLEDAI score
0.082
0.624
CR at 6 months
44 (63.8%)
18 (90%)
2.384
0.047
TR at 6 months
59 (85.5%)
19 (95%)
1.26
0.212
Note: when compared with the LN-non-B-cell group, there was a significant difference only at the disease duration and the CR for 6-month treatment in the LN-B-cell group. CR: complete remission; TR: total remission; dsDNA: double strand DNA; LN: lupus nephritis; AI: activity index; CI: chronicity index; SLEDAI: SLE disease activity index; expressed in (%); #expressed in median (interquartile range) and nonparameter test.
